Novellus, next generation non-immunogenic mRNA platform
입력 2018-09-12 09:04 수정 2018-09-17 13:21
바이오스펙테이터 Sungmin Kim 기자
A new mRNA company has emerged in the global biotechnology industry. Novellus, located in Boston, plans to enter clinical trials next year with a first-in-class mRNA gene editing therapy for a rare devasting genetic disease. Novellus is also considering an IPO in 2019. To date, companies in clinical trials with mRNA products have mainly focused on the development of vaccines, whereas Novellus believes that it holds the unique position of being able to address both genetic diseases and regenerative medicine using mRNA.
“We have been in stealth-mode until now in order to focus on the development of our technologies and intellectual property. Novellus has developed the first truly non-immunogenic mRNA platform. We are using this platform to develop mRNA-based gene editing therapies to permanently repair disease-causing genetic mutations and mRNA-based cell reprogramming therapies for making patient-specific cellular medicines. Novellus is the only company that has these two technology platforms and we plan to use them to address many diseases.”
Executive Vice President Paul Sowyrda introduced reporters from the Biospectator to the company’s therapeutic development strategy. In their new lab in Boston, the reporter met Dr. Frank Borriello M.D., a strategic consultant to the company, and Dr. Matthew Angel, the CSO, as well as Mr. Sowyrda.
Starting Point of Novellus: Factor Bioscience ‘Turning Technology into New Medicines’
Novellus spun out of Factor Bioscience, a biotechnology research company founded in 2011 by MIT graduates Dr. Matt Angel and Dr. Chris Rohde. Factor Bioscience holds many patents covering mRNA technologies, including ...